{
    "nct_id": "NCT04339036",
    "official_title": "UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors",
    "inclusion_criteria": "* Patients with confirmed diagnosis of histologic grade 2 neuroendocrine tumor with unresectable liver metastases (primary tumor or other extrahepatic disease may be present)\n* Patients with at least one measurable liver metastases, with size > 1cm (RECIST criteria)\n* Patients with liver dominant disease defined as ≥50% tumor body burden confined to the liver\n* Liver tumor burden does not exceed 50% of the liver volume\n* Patent main portal vein\n* At least 4 weeks since last administration of last chemotherapy and /or radiotherapy\n* Age >18 years.\n* Life expectancy of greater than 6 months.\n* ECOG performance status 0-2.\n* Adequate liver function as measured by: Total bilirubin ≤ 2.0mg/dl, ALT, AST ≤5 times ULN, albumin ≥2.5g/dl.\n* Patients must have adequate organ and marrow function as defined below:\n* platelets >100,000/mcL (may be corrected by transfusion)\n* serum creatinine < 2.0 mg/dl\n* INR <1.6, (may be corrected by transfusion)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Women of child bearing potential and fertile men are required to use effective contraception (negative urine or serum βHCG for women of child-bearing age)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Contraindications to capecitibine or temozolomide\n* Contraindicated for both contrast-enhanced MRI and CT\n* Patients previously treated with transarterial embolization (with or without chemotherapy) or with radioembolization (Y-90 microspheres)\n* Contraindication for radioembolization procedures:\n* excessive hepatopulmonary shunt as determined by the investigator\n* inability to deliver Y90 microspheres without risk of non-target embolization of extra-hepatic structures\n* Subjects consenting to the trial who fail their simulation angiography will be removed from the study and replaced.\n* Patients may not be receiving any other investigational agents.\n* Absolute contraindication to intravenous iodinated contrast (Hx of significant previous contrast reaction, not mitigated by appropriate pre-medication).\n* Choledochoenteric anastomosis, transpapillary stent or sphincterotomy of duodenal papilla;\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnant and lactating women are ineligible",
    "miscellaneous_criteria": ""
}